iSpecimen (NASDAQ:ISPC) Releases Earnings Results

iSpecimen (NASDAQ:ISPC) issued its quarterly earnings results on Friday. The company reported ($0.98) EPS for the quarter, FiscalAI reports. The business had revenue of $0.15 million for the quarter. iSpecimen had a negative net margin of 1,080.16% and a negative return on equity of 584.65%.

iSpecimen Price Performance

Shares of NASDAQ ISPC traded down $0.05 during trading on Friday, reaching $2.25. 38,846 shares of the stock traded hands, compared to its average volume of 62,931. iSpecimen has a 52-week low of $1.77 and a 52-week high of $127.20. The company has a 50-day moving average of $2.39 and a 200-day moving average of $5.79. The stock has a market capitalization of $3.42 million, a P/E ratio of -0.03 and a beta of 1.66.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of iSpecimen in a research report on Friday, July 17th. Wall Street Zen upgraded shares of iSpecimen to a “sell” rating in a research report on Saturday, May 2nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has a consensus rating of “Sell”.

Institutional Trading of iSpecimen

A hedge fund recently bought a new position in iSpecimen stock. Virtu Financial LLC bought a new position in shares of iSpecimen Inc. (NASDAQ:ISPC) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 63,257 shares of the company’s stock, valued at approximately $82,000. Virtu Financial LLC owned approximately 0.65% of iSpecimen at the end of the most recent reporting period. Hedge funds and other institutional investors own 13.62% of the company’s stock.

iSpecimen Company Profile

iSpecimen, Inc (NASDAQ:ISPC) operates an online life sciences marketplace designed to connect researchers with human biological specimens and associated clinical data. The company’s platform streamlines the sourcing of biospecimens—such as plasma, serum, fresh and frozen tissue, saliva, urine and peripheral blood mononuclear cells (PBMCs)—by matching demand from pharmaceutical, biotechnology, diagnostic and academic organizations with supply from a wide network of clinical sites and biobanks.

Through its on-demand procurement model, iSpecimen provides customized specimen collection and fulfillment services that help accelerate research timelines and improve data quality.